固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

NeuroGenomeX藥物發現公司發展新的大腦和神經係統疾病的治療。當前NeuroGenomeX發現程序集中在治療癲癇症和創傷性腦損傷的靶區。NeuroGenomeX推進其領導的候選藥物,2-deoxy-D-glucose (2 dg),作為一個抗驚厥的阻止癲癇發作和癲癇的有利影響與不利的長期後果。2 dg也已經顯示出良好的治療創傷性腦損傷的神經保護作用在動物模型(創傷性腦損傷)。

Konova提供抗肥胖藥物開發

SynDevRx已開發出一項技術,增加了活動和安全使用共軛小分子藥物的技術。公司的技術提高藥物的治療指數由集中活動的疾病。它為小分子提供可預測的和可靠的物理特性,可以加快開發時間和降低成本,同時提高PK概要文件。SynDevRx首席藥物候選人有關- 7320腫瘤市場目標,抑製MetAP2 -一種酶,獨立研究顯示腫瘤生長的關鍵,擴散和轉移。公司成立於2007年,位於劍橋,麻薩諸塞州。

核心動力是一個發展階段的公司專注於冷凍凍幹白細胞和幹細胞及其在室溫下保存和存儲。

每秒是GLP / GCP-compliant合同研究組織(CRO)提供最高等級的發現、臨床前和臨床藥物開發服務。關注bioanalytics和臨床試驗,每秒以證明質量標準,技術專長,一個靈活的方法來研究、客戶滿意度和交鑰匙實驗室和設備。